State Street Corp increased its position in Crispr Therapeutics AG (NASDAQ:CRSP) by 2.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 37,103 shares of the company’s stock after purchasing an additional 758 shares during the quarter. State Street Corp owned 0.07% of Crispr Therapeutics worth $1,521,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. BNP Paribas Arbitrage SA acquired a new stake in Crispr Therapeutics during the second quarter worth $41,000. Aperio Group LLC bought a new stake in Crispr Therapeutics during the second quarter valued at about $153,000. Trexquant Investment LP bought a new stake in Crispr Therapeutics during the second quarter valued at about $466,000. LPL Financial LLC raised its holdings in Crispr Therapeutics by 303.6% during the second quarter. LPL Financial LLC now owns 33,298 shares of the company’s stock valued at $1,568,000 after acquiring an additional 25,047 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in Crispr Therapeutics by 116.5% during the second quarter. Bank of New York Mellon Corp now owns 33,091 shares of the company’s stock valued at $1,559,000 after acquiring an additional 17,810 shares during the period. Hedge funds and other institutional investors own 49.83% of the company’s stock.
In related news, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the sale, the president now directly owns 33,618 shares in the company, valued at approximately $2,353,260. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total transaction of $412,500.00. Following the sale, the director now owns 7,500 shares in the company, valued at $412,500. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 56,118 shares of company stock valued at $3,620,760. Corporate insiders own 21.40% of the company’s stock.
Shares of CRSP stock traded down $1.82 during mid-day trading on Friday, hitting $54.75. 1,224,856 shares of the stock were exchanged, compared to its average volume of 1,021,665. The firm has a fifty day moving average of $63.18 and a 200 day moving average of $52.50. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. Crispr Therapeutics AG has a 52-week low of $29.34 and a 52-week high of $74.00. The company has a market cap of $3.12 billion, a PE ratio of -119.02 and a beta of 3.20.
Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $3.35. The business had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. Equities analysts predict that Crispr Therapeutics AG will post 0.65 EPS for the current year.
A number of equities research analysts have commented on CRSP shares. Piper Jaffray Companies reissued a “buy” rating and set a $104.00 price target on shares of Crispr Therapeutics in a report on Monday, December 16th. Roth Capital upped their price target on Crispr Therapeutics from $65.00 to $100.00 in a research report on Tuesday, November 19th. Oppenheimer upped their target price on Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a research report on Monday, November 25th. Zacks Investment Research lowered shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 30th. Finally, Canaccord Genuity upped their price target on shares of Crispr Therapeutics from $72.00 to $80.00 and gave the company a “positive” rating in a report on Wednesday, November 20th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and twelve have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $75.95.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
See Also: How to identify percentage decliners
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.